Read the latest news about clinical trials on Alzheimer's prevention with the participation of the Barcelonaβeta Brain Research Center (BBRC).
The international study Skyline plans to enroll 1.200 participants worldwide to assess a new treatment against Alzheimer's disease.
The last drug approved by the FDA was in 2003, and until now any treatment has proved to slow down the progression of the disease.
Dr José Luis Molinuevo comments the possible approval of Biogen’s new treatment, in an interview for the podcast Saving Minds.
BBRC participates with the PENSA study
The PENSA Study will combine a program of interventions in lifestyle habits and the ingestion of a preparation based on a component from the green tea
The scientific director of BBRC's Alzheimer’s Prevention Program suggests trying a new aproach in order to keep working with Aducanumab
CTAD conference took place in Barcelona, from the 24th to the 27th of October.
The studies will analyze the efficacy of various pharmacological treatments designed to act before the manifestation of the clinical symptoms of the disease.